Stack
NAD+ with Epitalon
The commonly run longevity pairing, and the one where the two compounds' problems are different: NAD+ has a delivery problem, Epitalon has a replication problem.
These are combined because they are both marketed against ageing, not because anything connects their mechanisms. It is worth being clear about that: the stack is a category, not a strategy.
NAD+ itself is the better-understood molecule and the harder one to use. Its role in cellular metabolism is not in question; what is in question is whether administering the molecule itself, instead of a precursor, raises the levels that matter, and injected NAD+ is widely reported to be uncomfortable at the doses people use.
Epitalon rests on a body of Russian work from the 1990s and 2000s reporting effects on telomerase and lifespan. That literature has not been independently replicated outside the group that produced it, which is a specific and serious gap, not a general shortage of evidence.
Run as short courses with long breaks rather than continuously, which is how both are usually described, and which at least limits exposure to compounds this poorly characterised.
The schedule
Commonly run, not recommended10 weeks. Doses are what sources describe rather than what we advise — where a source gave a range we show the range instead of choosing a number inside it.
| Compound | Dose | How often | Weeks |
|---|---|---|---|
| NAD+Early human trialsThe metabolic half. Administered directly rather than as a precursor, which is the contested choice. | 20 mg–100 mg | Every 2 daysInjection discomfort is the most consistently reported effect and it scales with dose and speed. Slower administration at a lower dose is the usual answer, and oral precursors are the alternative people move to. | 1–10 |
| EpitalonPreclinicalThe peptide half. Short course, on the telomerase literature. | 5 mg–10 mg | Once dailyDescribed as a ten-to-twenty-day course two or three times a year rather than as continuous use. The dose figures come from the original Russian protocols. | 1–3 |
Things worth knowing
- Neither compound has an outcome you can measure at home. Longevity is not a readout available on any timescale you will be tracking, so anything you notice is being attributed to a stack that cannot be evaluated by noticing things.
- The Epitalon literature's replication gap is the single most important fact about this stack, and it is a gap in independent confirmation, not an absence of published claims.
- Injected NAD+ discomfort is not a sign of anything working. It is the most reliable effect either compound produces, and it is the one people most often read as evidence.
- Both are sold as research chemicals with no pharmacopoeial standard.
Related
Questions
- Why are these two run together?
- Because both are marketed against ageing, not because their mechanisms connect. It is worth saying plainly: this stack is a category rather than a strategy, and no argument links inhibiting cellular ageing by one route to doing it by the other.
- Why is injected NAD+ so uncomfortable?
- It is the most consistently reported effect of the compound, it scales with dose and with how fast the injection is given, and it is not evidence of anything working. Slower administration at a lower dose is the usual response; oral precursors are what people move to when they stop tolerating it.
- Is the Epitalon research real?
- It is published. The issue is narrower and more serious than that framing suggests: the work reporting telomerase and lifespan effects comes largely from one research group in Russia and has not been independently replicated. That is a gap in confirmation, not an absence of papers.
- How would I know if this is doing anything?
- You would not. Longevity has no readout available on the timescale anyone tracks, so there is nothing you could log that bears on the question. That makes this stack unusual among the ones here, and it is better known before starting than after.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.